This lesion persisted in CD34+/CD38-/CD90+ MDS HSCs despite continuous lenalidomide treatment, consistent with MDS HSCs being relative resistant to therapy and the source of disease maintenance/re-emergence following therapy (Nilsson et al., 2007; Tehranchi et al., 2010). The gene discussed is CD34; the disease is myelodysplastic syndrome.